Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 05

1859P - Digital goal management training as treatment for cognitive impairment in cervical cancer survivors: A feasibility study

Date

21 Oct 2023

Session

Poster session 05

Topics

Supportive Care and Symptom Management;  Psycho-Oncology;  Survivorship

Tumour Site

Gynaecological Malignancies

Presenters

Elisabeth Areklett

Citation

Annals of Oncology (2023) 34 (suppl_2): S1001-S1012. 10.1016/S0923-7534(23)01947-6

Authors

E.W. Areklett1, B.I. Hagen2, S. Andersson3, K. Bruheim4, E. Fagereng5, J. Stubberud3, K. Lindemann6

Author affiliations

  • 1 Department Of Oncology, Oslo University Hospital - The Norwegian Radium Hospital, 0424 - Oslo/NO
  • 2 Department Of Social Education, UiT The Arctic University of Norway, 9404 - Harstad/NO
  • 3 Department Of Psychology, University of Oslo, 0316 - Oslo/NO
  • 4 Department Of Oncology, Oslo University Hospital - The Norwegian Radium Hospital, 0379 - Oslo/NO
  • 5 Trs National Resource Centre For Rare Disorders, Sunnaas Rehabilitation hospital, 1453 - Bjørnemyr/NO
  • 6 Department Of Gynecological Cancer, Oslo University Hospital - The Norwegian Radium Hospital, 0424 - Oslo/NO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1859P

Background

Cognitive impairment (CI) is a common late effect after cancer treatment, for which effective treatment is lacking. Goal Management Training (GMT) is a validated cognitive remediation protocol reported to improve cognition including perceived daily life executive functioning, in neurological conditions. However, GMT has never been examined in cancer survivors, nor been presented in a digital format. This study examined the feasibility and acceptability of digital GMT in cervical cancer survivors (CCS) with subjective and/or objective CI.

Methods

We invited 65 CCS with CI to participate. Participants were randomized in a 1:1 ratio between digital GMT and a computerized cognitive training (CCT) program (BrainHQ). GMT consists of six weekly group-based modules encompassing discussion of participants’ real-life cognitive deficits, practice on tasks of attention and self-monitoring, as well as homework assignments. BrainHQ is a web-based training platform with exercises targeting several cognitive domains. For six weeks, participants joined digital training sessions of one hour twice a week. The primary endpoint was attendance, and participants attending ≥80% of the sessions were categorized as completers. Acceptability was evaluated 1 week post-intervention using the Client Satisfaction Questionnaire-8 (CSQ-8). A total CSQ-8 score ≥ 26 was defined as “very satisfied”, scores 20-25 as “satisfied”, and scores <20 as “not satisfied”.

Results

33 CCS with a median age of 50.0 years (range 35-67) were randomized to either GMT (N = 16) or CCT (N = 17). In the GMT group, all participants completed the intervention (100%), compared to 15 (88%) in the CCT group. Median CSQ-8 in the GMT and CCT group was 25 (SD 3.7, range 18-31) and 24 (SD 3.1, range 19-30) respectively. Participants in both groups reported a high level of satisfaction as 40% reported being “very satisfied” and 53% “satisfied”.

Conclusions

A digital cognitive training program such as GMT is feasible with a high level of compliance and satisfaction in CCS and is suitable to be tested in a larger study. Exploratory analyses of neuropsychological assessments in our study will provide important preliminary data on the efficacy of improving cognitive function in CCS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Jan Kåre Heiberg and Marthe Vildåsen.

Disclosure

K. lindemann: Financial Interests, Institutional, Research Grant, Grants or contracts, paid to institution: GSK; Financial Interests, Institutional, Advisory Board, Participation on Data Safety Monitoring/advisory board: Eisai, MSD, Nycode, AstraZeneca, GSK. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.